Vendor Intelligence Report: Wuhan Muwang Trading

Published 2 Jul 2026. 15-page investigative report on who is behind Wuhan Muwang Trading: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Wuhan Muwang Trading is 4 pass / 0 fail, for an overall pass rate of 100%. The record is narrow but useful: every sample in the current dataset is Tirzepatide, and each passed, with a buyer-facing Finnrick rating of 82.61%. For Tirzepatide specifically, Wuhan Muwang Trading shows a real sourcing capability; for any other peptide, the report does not support borrowing that confidence across the catalog. The full dossier also shows how the score changes across stricter Finnrick grading models.

The identity story is less clean than the lab story. The listed Made-in-China showroom for Wuhan Muwang Trading was no longer accessible during the field run and had no Wayback snapshots, while a related Dingwang/Senwayer showroom remained live. A Chinese registry record, supplier-directory traces, and platform evidence point to Muwang as a legacy or dormant trading-name channel within a broader Wuhan network, but the link is circumstantial rather than a single definitive corporate filing.

That distinction matters for buyers. The strongest public company record names Dingwang Technology, not Muwang; the only named person in the registry trail is a legal representative for Dingwang; and the claimed manufacturing footprint could not be verified to facility addresses, FDA registrations, or peptide-production certifications. The dossier also weighs a detailed linked-Senwayer buyer complaint involving wrong items, communication gaps, tracking irregularities, and marketplace escalation.

Inside the full report:

  • Appendix A laboratory data, methodology-divergence charts, and the Tirzepatide rating trajectory
  • CNVerify registration exhibit for Dingwang Technology and the named legal representative
  • Made-in-China, Senwayer, ChemicalBook, Echemi, Freshdi, and PeppyCheck footprint comparison
  • Manufacturing-claim traceability review covering facility addresses, FDA registration, and QA certifications
  • Annotated buyer-complaint evidence from the linked Senwayer channel
  • CBP, DEA, ICE, and Brookings context for Chinese peptide importability and Wuhan/Hubei supplier risk

Risk assessment

  • Corporate-identity and source-transparency risk — high: The Muwang storefront was inaccessible, no Muwang registry record was found, and the current channel appears to run through Dingwang/Senwayer without facility-level manufacturing transparency.
  • Fulfillment-integrity risk — high: A detailed linked-Senwayer buyer report described wrong products, alleged fake tracking numbers, radio silence, and dispute-driven partial refund; limited sample, but high severity for injectable products.
  • U.S. import seizure and disruption risk — medium: No vendor-specific enforcement action surfaced, but Chinese peptide shipments including Tirzepatide are under active CBP scrutiny and mis-manifesting enforcement has intensified.